
Opinion|Videos|November 12, 2024
Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What factors do you consider when choosing between quadruplet or triplet therapy in transplant-preferred newly diagnosed multiple myeloma (NDMM)?
Advertisement
Related to this article

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
2
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
When to Pause or Stop Therapy in Advanced RCC
5

